3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
24
Fallopian Tube Neoplasms
13
Neoplasms
11
Breast Neoplasms
11
Triple Negative Breast Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Solid Tumors
4
Sarcoma
4
Neoplasm Metastasis
4
Sarcoma, Ewing
3
Lymphoma
3
Carcinoma
3
Sarcoma, Kaposi
2
Rhabdomyosarcoma
2
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Advanced Solid Tumors
2
AIDS-related Kaposi sarcoma
2
Urinary Bladder Neoplasms
1
Unrecognized Condition
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Interventions
Cyclophosphamide
38
fludarabine
30
Rituximab
26
obinutuzumab
10
Bendamustine Hydrochloride
10
fludarabine phosphate
9
pembrolizumab
8
Specimen Handling
7
Etoposide
7
venetoclax
6
Vincristine
6
Prednisone
6
Magnetic Resonance Spectroscopy
6
Leukapheresis
6
Lenalidomide
6
ibrutinib
5
Inotuzumab Ozogamicin
5
Immunotherapy, Adoptive
5
Doxorubicin
5
Biopsy
5
ublituximab
4
tazemetostat
4
glofitamab
4
Interleukin-2
4
Dexamethasone
4
Cytarabine
4
pomalidomide
3
polatuzumab vedotin
3
Radiation
3
Nivolumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, B-Cell
×
liposomal doxorubicin
×
Clear all
NCT05270057
2025-10-09
LONCA
Medical College of Wisconsin
Phase 1
Active not recruiting
11 enrolled